Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap |
|---|
| Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
PF PFE PFIZER INC FY ended Feb 19, 2026 | $27.96 | $159.36B | $176.96B | $62.58B | $15.48B | $7.77B | 20.56x | 2.55x | 9.71x |
JN JNJ JOHNSON & JOHNSON FY ended Feb 06, 2026 | $268.04 | $645.95B | $703.36B | $94.19B | $37.95B | $26.80B | 24.30x | 6.86x | 17.67x |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
NV NVAX NOVAVAX INC FY ended Feb 16, 2026 | $9.26 | $1.53B | $1.14B | $1.12B | $456.98M | $440.30M | 3.59x | 1.36x | 2.41x |
VR VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026 | $541.69 | $137.30B | $134.75B | $12.00B | $4.88B | $3.95B | 35.36x | 11.44x | 27.38x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 14.54x | 6/6 | -$39.82B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 5.78x | 6/6 | $11.24B | $28.16 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 22.61x | 6/6 | -$63.82B | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
PF PFE PFIZER INC FY ended Feb 19, 2026 | $27.96 | $159.36B | $176.96B | $62.58B | $15.48B | $7.77B | 20.56x | 2.55x | 9.71x |
JN JNJ JOHNSON & JOHNSON FY ended Feb 06, 2026 | $268.04 | $645.95B | $703.36B | $94.19B | $37.95B | $26.80B | 24.30x | 6.86x | 17.67x |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
NV NVAX NOVAVAX INC FY ended Feb 16, 2026 | $9.26 | $1.53B | $1.14B | $1.12B | $456.98M | $440.30M | 3.59x | 1.36x | 2.41x |
VR VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026 | $541.69 | $137.30B | $134.75B | $12.00B | $4.88B | $3.95B | 35.36x | 11.44x | 27.38x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 14.54x | 6/6 | -$39.82B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 5.78x | 6/6 | $11.24B | $28.16 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 22.61x | 6/6 | -$63.82B | — | Target fundamentals do not produce a usable positive equity value. |